Nature:HIV-1与其制约因子SAMHD1之间的关系

2014-01-17 Nature中文网 Nature中文网

SAMHD1是人体细胞中产生的一种酶,起针对“人免疫缺陷病毒-1”(HIV-1)的制约因子的作用,阻断病毒对骨髓细胞和CD4+ T细胞的感染。 该病毒对抗“辅助蛋白”Vpx,后者以SAMHD1为目标来使蛋白酶体降解。现在,Ian Taylor及同事提供了显示Vpx怎样将SAMHD1吸引到细胞的“泛素化”机构中去的一个结构。 由Vpx与E3连接酶基质转接蛋白DCAF1 和SAMHD1一起形成

SAMHD1是人体细胞中产生的一种酶,起针对“人免疫缺陷病毒-1”(HIV-1)的制约因子的作用,阻断病毒对骨髓细胞和CD4+ T细胞的感染。

该病毒对抗“辅助蛋白”Vpx,后者以SAMHD1为目标来使蛋白酶体降解。现在,Ian Taylor及同事提供了显示Vpx怎样将SAMHD1吸引到细胞的“泛素化”机构中去的一个结构。

由Vpx与E3连接酶基质转接蛋白DCAF1 和SAMHD1一起形成的一个三元复合物的这一晶体结构显示,Vpx包裹在DCAF1周围,改变其形状,使其能够通过它的C-端点来吸收SAMHD1。【原文下载】

原文出处:

Abstract:

Lentiviruses contain accessory genes that have evolved to counteract the effects of host cellular defence proteins that inhibit productive infection. One such restriction factor, SAMHD1, inhibits human immunodeficiency virus (HIV)-1 infection of myeloid-lineage cells as well as resting CD4(+) T cells by reducing the cellular deoxynucleoside 5'-triphosphate (dNTP) concentration to a level at which the viral reverse transcriptase cannot function. In other lentiviruses, including HIV-2 and related simian immunodeficiency viruses (SIVs), SAMHD1 restriction is overcome by the action of viral accessory protein x (Vpx) or the related viral protein r (Vpr) that target and recruit SAMHD1 for proteasomal degradation. The molecular mechanism by which these viral proteins are able to usurp the host cell's ubiquitination machinery to destroy the cell's protection against these viruses has not been defined. Here we present the crystal structure of a ternary complex of Vpx with the human E3 ligase substrate adaptor DCAF1 and the carboxy-terminal region of human SAMHD1. Vpx is made up of a three-helical bundle stabilized by a zinc finger motif, and wraps tightly around the disc-shaped DCAF1 molecule to present a new molecular surface. This adapted surface is then able to recruit SAMHD1 via its C terminus, making it a competent substrate for the E3 ligase to mark for proteasomal degradation. The structure reported here provides a molecular description of how a lentiviral accessory protein is able to subvert the cell's normal protein degradation pathway to inactivate the cellular viral defence system.

Schwefel D1, Groom HC2, Boucherit VC2, Christodoulou E1, Walker PA1, Stoye JP2, Bishop KN2, Taylor IA1.Structural basis of lentiviral subversion of a cellular protein degradation pathway.Nature. 2014 Jan 9;505(7482):234-8. doi: 10.1038/nature12815. Epub 2013 Dec 15.【原文下载】

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2057555, encodeId=00a2205e55515, content=<a href='/topic/show?id=77f1116e486' target=_blank style='color:#2F92EE;'>#MHD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11674, encryptionId=77f1116e486, topicName=MHD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Wed Nov 12 19:19:00 CST 2014, time=2014-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062429, encodeId=bb2c206242925, content=<a href='/topic/show?id=4c3d241806' target=_blank style='color:#2F92EE;'>#AMH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2418, encryptionId=4c3d241806, topicName=AMH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Mon Jun 09 17:19:00 CST 2014, time=2014-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084004, encodeId=5eae2084004b0, content=<a href='/topic/show?id=17a61586256' target=_blank style='color:#2F92EE;'>#SAMHD1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15862, encryptionId=17a61586256, topicName=SAMHD1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c49e75, createdName=qjddjq, createdTime=Wed Apr 23 21:19:00 CST 2014, time=2014-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879869, encodeId=560218e986947, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Aug 31 04:19:00 CST 2014, time=2014-08-31, status=1, ipAttribution=)]
    2014-11-12 xugumin
  2. [GetPortalCommentsPageByObjectIdResponse(id=2057555, encodeId=00a2205e55515, content=<a href='/topic/show?id=77f1116e486' target=_blank style='color:#2F92EE;'>#MHD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11674, encryptionId=77f1116e486, topicName=MHD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Wed Nov 12 19:19:00 CST 2014, time=2014-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062429, encodeId=bb2c206242925, content=<a href='/topic/show?id=4c3d241806' target=_blank style='color:#2F92EE;'>#AMH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2418, encryptionId=4c3d241806, topicName=AMH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Mon Jun 09 17:19:00 CST 2014, time=2014-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084004, encodeId=5eae2084004b0, content=<a href='/topic/show?id=17a61586256' target=_blank style='color:#2F92EE;'>#SAMHD1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15862, encryptionId=17a61586256, topicName=SAMHD1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c49e75, createdName=qjddjq, createdTime=Wed Apr 23 21:19:00 CST 2014, time=2014-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879869, encodeId=560218e986947, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Aug 31 04:19:00 CST 2014, time=2014-08-31, status=1, ipAttribution=)]
    2014-06-09 fengyi812
  3. [GetPortalCommentsPageByObjectIdResponse(id=2057555, encodeId=00a2205e55515, content=<a href='/topic/show?id=77f1116e486' target=_blank style='color:#2F92EE;'>#MHD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11674, encryptionId=77f1116e486, topicName=MHD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Wed Nov 12 19:19:00 CST 2014, time=2014-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062429, encodeId=bb2c206242925, content=<a href='/topic/show?id=4c3d241806' target=_blank style='color:#2F92EE;'>#AMH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2418, encryptionId=4c3d241806, topicName=AMH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Mon Jun 09 17:19:00 CST 2014, time=2014-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084004, encodeId=5eae2084004b0, content=<a href='/topic/show?id=17a61586256' target=_blank style='color:#2F92EE;'>#SAMHD1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15862, encryptionId=17a61586256, topicName=SAMHD1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c49e75, createdName=qjddjq, createdTime=Wed Apr 23 21:19:00 CST 2014, time=2014-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879869, encodeId=560218e986947, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Aug 31 04:19:00 CST 2014, time=2014-08-31, status=1, ipAttribution=)]
    2014-04-23 qjddjq
  4. [GetPortalCommentsPageByObjectIdResponse(id=2057555, encodeId=00a2205e55515, content=<a href='/topic/show?id=77f1116e486' target=_blank style='color:#2F92EE;'>#MHD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11674, encryptionId=77f1116e486, topicName=MHD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Wed Nov 12 19:19:00 CST 2014, time=2014-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062429, encodeId=bb2c206242925, content=<a href='/topic/show?id=4c3d241806' target=_blank style='color:#2F92EE;'>#AMH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2418, encryptionId=4c3d241806, topicName=AMH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Mon Jun 09 17:19:00 CST 2014, time=2014-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084004, encodeId=5eae2084004b0, content=<a href='/topic/show?id=17a61586256' target=_blank style='color:#2F92EE;'>#SAMHD1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15862, encryptionId=17a61586256, topicName=SAMHD1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c49e75, createdName=qjddjq, createdTime=Wed Apr 23 21:19:00 CST 2014, time=2014-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879869, encodeId=560218e986947, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Aug 31 04:19:00 CST 2014, time=2014-08-31, status=1, ipAttribution=)]
    2014-08-31 liye789132251

相关资讯

AIDS:中缅边境地区注射吸毒人群HIV-1分子流行病学研究获进展

吸毒人群是我国HIV-1感染的高危人群,注射吸毒(Injecting Drug Users, IDUs) 尤其是跨境注射吸毒导致的艾滋病重组流行已成为我国艾滋病传播的重要途径之一。由于毗邻著名的毒品生产基地“金三角”,云南省特别是边境地区的吸毒现象较为普遍。1989年年底,我国在云南省瑞丽市吸毒者中首次发现规模人群感染艾滋病。在过去的回顾性研究中,发现印度HIV-1 B’亚型和泰国C亚型,沿着毒品

Lancet:HIV-1成年患者中Dolutegravir疗效优于Raltegravir(SAILING 研究)

  Dolutegravir(GSK1349572)是一种每日用药一次的HIV整合酶抑制剂,具有强有力的抗抗病毒作用,并且疗效安全。为了评估Dolutegravir在既往接受过抗反转录病毒治疗但未接受过整合酶抑制剂治疗,并且对至少两种类型的药物耐药的HIV-1成年患者的安全性、有效性和即刻耐药反应,来自阿根廷Huesped基金会的Pedro Cahn等设计了相关研究,研究结

JBC:结核病人更容易感染HIV-1

众所周知,感染结核杆菌的病人更可能会感染HIV-1,但是结核杆菌刺激HIV-1长末端重复序列(LTR)的转录机制尚不明确。近日,印度DNA指纹诊断中心的Sangita Mukhopadhyay等人研究发现,结核杆菌PPE蛋白Rv1168c能够增强HIV-1 LTR启动子的转录,该研究促进了HIV-1及结核杆菌共同感染病人中HIV-1发病学的研究,相关论文发表在3月15日美国《生化周刊》(JBC)上